PFIZER INC. v. RANBAXY LABORATORIES LIMITED and RANBAXY PHARMACEUTICALS, INC. (Lipitor)
N/AOUTCOME:
The litigation was directed to Pfizer's Lipitor, with revenues of 12.9 billion annual sales of the drug at its peak. In Pfizer, Inc. v. Ranbaxy Laboratories Ltd., No. 06-1179 (Fed. Cir. Aug. 2, 2006), ... the Federal Circuit affirmed a district court’s finding of infringement of U.S. Patent No. 4,681,893 (“the ’893 patent”) and ruling that the ’893 patent term extension was not invalid. The Federal Circuit reversed on the question of invalidity of U.S. Patent No. 5,273,995 (“the ’995 patent”) pursuant to 35 U.S.C. § 112, ¶ 4. In doing so, the Court reiterated that the fourth paragraph of § 112 is an invalidating provision.
